Biotech News

Organogenesis Applauds CMS’s Significant Step In Payment Reform

Organogenesis (ORGO)OrganogenesisFDA / regulatory

With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond CANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company

Related news

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

Stock data

Close
2.41 USD
Market cap
288.23M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States